A Study of BG-C477 in Participants With Advanced Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
City of Hope National Medical Center, Duarte, California Yale University, Yale Cancer Center, New Haven, Connecticut The University of Kansas Cancer Center, Westwood, Kansas John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey The University of Texas Md Anderson Cancer Center, Houston, Texas Australia
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales Northern Beaches Hospital, Frenchs Forest, New South Wales Sunshine Coast University Private Hospital, Birtinya, Queensland Cancer Research South Australia, Adelaide, South Australia The Alfred Hospital, Melbourne, Victoria One Clinical Research, Nedlands, Western Australia China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Beijing Chest Hospital, Capital Medical University, Beijing, Beijing Municipality Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality Sun Yat Sen University Cancer Center, Guangzhou, Guangdong Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Guangxi Medical University Cancer Hospital Wuxiang Branch, Nanning, Guangxi Jiamusi Cancer Hospital, Jiamusi, Heilongjiang Hubei Cancer Hospital, Wuhan, Hubei Jiangxi Cancer Hospital, Nanchang, Jiangxi The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang, Jiangxi Jining No1 Peoples Hospital East Branch, Jining, Shandong Linyi Peoples Hospital Beicheng Branch, Linyi, Shandong New Zealand
Auckland City Hospital, Auckland Taizhou Hospital of Zhejiang Province (East), Taizhou, Zhejiang